CACCIARI, Barbara
 Distribuzione geografica
Continente #
NA - Nord America 11.668
AS - Asia 6.062
EU - Europa 4.744
SA - Sud America 1.035
Continente sconosciuto - Info sul continente non disponibili 123
AF - Africa 92
OC - Oceania 6
Totale 23.730
Nazione #
US - Stati Uniti d'America 11.438
FI - Finlandia 2.064
SG - Singapore 2.049
CN - Cina 1.693
BR - Brasile 800
UA - Ucraina 696
VN - Vietnam 664
DE - Germania 517
HK - Hong Kong 508
TR - Turchia 482
GB - Regno Unito 366
IT - Italia 253
SE - Svezia 235
FR - Francia 212
RU - Federazione Russa 157
BD - Bangladesh 138
IN - India 122
JP - Giappone 119
MX - Messico 106
CA - Canada 95
AR - Argentina 85
PL - Polonia 68
EC - Ecuador 44
ID - Indonesia 43
ZA - Sudafrica 42
IQ - Iraq 41
NL - Olanda 33
PK - Pakistan 33
CO - Colombia 30
ES - Italia 24
BE - Belgio 23
VE - Venezuela 23
SA - Arabia Saudita 20
PY - Paraguay 18
PH - Filippine 17
MY - Malesia 16
UZ - Uzbekistan 16
LT - Lituania 13
MA - Marocco 13
TW - Taiwan 13
AE - Emirati Arabi Uniti 12
CL - Cile 12
IE - Irlanda 12
AT - Austria 11
PE - Perù 11
TN - Tunisia 10
KZ - Kazakistan 8
AL - Albania 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
JO - Giordania 7
NP - Nepal 7
AZ - Azerbaigian 6
LB - Libano 6
UY - Uruguay 6
BO - Bolivia 5
CH - Svizzera 5
EG - Egitto 5
IR - Iran 5
KE - Kenya 5
KG - Kirghizistan 5
KR - Corea 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AU - Australia 4
BG - Bulgaria 4
BY - Bielorussia 4
DK - Danimarca 4
ET - Etiopia 4
HN - Honduras 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
KW - Kuwait 3
MN - Mongolia 3
PS - Palestinian Territory 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CI - Costa d'Avorio 2
HU - Ungheria 2
IL - Israele 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
ME - Montenegro 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
AF - Afghanistan, Repubblica islamica di 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
Totale 23.593
Città #
Helsinki 1.915
Singapore 1.278
Ashburn 1.208
Woodbridge 977
Fairfield 914
Dallas 863
Houston 780
Jacksonville 714
San Jose 599
Chandler 593
Hong Kong 496
Ann Arbor 488
Santa Clara 467
Beijing 412
Seattle 367
Wilmington 358
Cambridge 264
Nanjing 243
Izmir 222
Ho Chi Minh City 213
Princeton 160
Hanoi 153
Los Angeles 141
Lauterbourg 117
Tokyo 114
Boardman 112
San Diego 91
Council Bluffs 90
New York 87
Shenyang 77
São Paulo 77
Nanchang 67
Mexico City 66
Munich 62
Dong Ket 61
Hefei 60
Warsaw 58
Orem 52
Milan 48
Shanghai 48
Ferrara 44
Jiaxing 41
Tianjin 41
Brooklyn 38
Buffalo 37
San Mateo 37
London 36
Falkenstein 34
Hebei 34
Chicago 33
Kunming 32
Changsha 31
Jinan 31
Zhengzhou 31
Chennai 30
Dearborn 30
Rio de Janeiro 29
San Francisco 28
Da Nang 27
Frankfurt am Main 27
Falls Church 26
Philadelphia 25
Montreal 24
Phoenix 23
Toronto 23
Amsterdam 22
Brussels 22
Norwalk 22
Denver 21
Moscow 21
Haiphong 20
Manchester 20
Stockholm 20
Baghdad 19
Jakarta 19
Johannesburg 19
Ningbo 19
Turku 19
Guangzhou 18
The Dalles 18
Addison 17
Istanbul 16
Atlanta 15
Biên Hòa 15
Hải Dương 15
Mountain View 15
Bremen 14
Taizhou 14
Tashkent 14
Curitiba 13
Quito 13
Rome 13
Verona 13
Boston 12
Dublin 12
Guayaquil 12
Montréal 12
Mumbai 12
Porto Alegre 12
Redwood City 12
Totale 16.474
Nome #
1,2,3-triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new class of A(2A) adenosine receptor antagonists 3.047
[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1 531
1-methyl-3-nitro-5-methoxycarbonyl pyrazole 292
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 268
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 252
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 245
Antiproliferative effects of novel synthetic nucleobase analogues on U937 Histiocytic lymphoma cell line 239
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 228
1H-pyrazolo[2,3-d][1,2,4]triazine-3,7-diones as a new class of human leukocyte elastase inhibitors 224
Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1,4] benzodiazepine and minor-groove-binding oligopyrrole carriers 223
Schematic overview of oligosaccharides, with survey on their major physiological effects and a focus on milk ones 221
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 212
A new synthetic approach to indazole synthesis 211
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 209
Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach 208
8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands 205
1H-pyrazolo[4,3-d]pyrimidine-7(6H)-one and 5H-pyrazolo[4,3-d] 1,2,3-triazin-4(3H)-one derivatives. Synthesis and in vitro biological activity at adenosine A1 and A2a receptors 204
[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 202
[3H]MRE3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 196
7-sobstituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonist: importance of modifications at the side chain on the activity and solubility. 192
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 190
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 189
New potent and selective human adenosine A3 receptor antagonists. 186
Synthesis and properties of substituted CBI analogs of CC-1065 and the duocarmycins incorporating the 7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (MCBI) alkylation subunit: Magnitude of electronic effects on the functional reactivity 185
Solid lipid microparticles for the stability enhancement of a dopamine prodrug 182
New potent and selective human adenosine A3 receptor antagonists 180
Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: A further validation of the relationship between chemical solvolytic stability and cytotoxicity 177
Synthesis and antitumor activity of novel distamycin derivatives 176
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo- pyrimidine antagonists binding site of the human adenosine A2A receptor 172
A novel class of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A3 adenosine receptor antagonists 172
Oligonucleotides and oligonucleotide conjugates: A new approach for cancer treatment 171
Synthesis and calcium antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(nitrogenous heteroaryl)-3,5-pyridine dicarboxylates. 171
Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones 170
A(1) and A(3) adenosine receptor agonists: an overview 170
Carbon nanotube substrates boost neuronal electrical signaling 168
DNA minor groove alkylating agents structurally related to distamycin A 167
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists 166
Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines (PBDs) 166
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 165
Recent developments in the field of adenosine receptor ligands 164
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 164
A Novel Conjugated Agent between Dopamine and an A(2A) Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. 160
A2A-adenosine receptor reserve for coronary vasodilation 159
Synthesis and biological evaluation of new antitubulin agents containing 2-(30,40,50-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold 157
DNA minor-groove binders: results and design of new antitumor agents 156
Chemical Synthesis of [13C]Daidzein 156
Ethyl (R,S)-5-acetyl-4,5-dihydro-3-isoxazoleacetate 156
Synthesis and Antitumor Activity of a New Class of Pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone Analogs of Pyrrolo[1,4][2,1-c]benzodiazepines 156
Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A(2A) Adenosine Receptor Antagonists with Improved Water Solubility 156
A(3) adenosine receptor ligands: History and perspectives 155
An efficient procedure for the synthesis of 5H-6-substituted-pyrazolo[1,5-d]-1,2,4-triazine-4,7-diones 155
Ethyl-(R,S)-5-acetyl-4,5-dihydro-3-isoxazole acetate 154
Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid 153
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile 153
Cosmetic preservation and structure-activity relationships of 4-diazo-pyrazole-5-carboxamides 153
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists 153
Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c] [1,4]benzodiazepines 153
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes 152
Structure-activity relationship of novel tallimustine derivatives: Synthesis and antitumor activity 151
The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA3 Adenosine Receptors Antagonists: New Insights into Structure-Affinity Relationship and Receptor-Antagonist Recognition 150
Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents 150
Facile and versatile route to the synthesis of fused 2-pyridones: Useful intermediates for polycyclic sytems 148
Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists 148
Unusual Ring-Opening Reaction of 6,7-Dihydrothieno[3,2-d]pyrimidine- 2,4-dione Derivatives Leading to 5-(Alkylthio)-6-vinyluracils 148
Synthesis and preliminary biological evaluation of [H-3]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A(3) adenosine receptors 147
Selective binding to human genomic sequences of two synthetic analogues structurally related to U-71184 and adozelesin 147
Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: Irreversible antagonists at the human A(3) adenosine receptor and molecular modeling studies 144
CC-1065 and the duocarmycins: recent developments 141
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists 141
Synthesis of pyridazine derivatives through the unexpected intermediate 5-amino-4-cyano-2,3-dihydro-furan-2,3-disulfonic acid disodium salt 141
Carbon Nanotubes Carrying Cell-Adhesion Peptides do not Interfere with Neuronal Functionality 140
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling 139
Pyrazolo [4,3-E]1,2,4-triazolo[1,5-c]pyrimidine derivates a new class of potent and selective human A3 adenosine receptor antagonists. 137
Pyridazine nucleus: a pharmacophoric moiety for bio-active compounds 136
Exploring Potency and Selectivity Receptor Antagonist Profiles Using a Multilabel Classification Approach: The Human Adenosine Receptors as a Key Study 136
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 136
Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridinedicarboxylates. 2 133
Synthesis of the tritium labeled SCH 58261, a new non-xanthine A(2A) adenosine receptor antagonist 130
Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A(2A) antagonists 129
Conjugation of Dopamine and an A2A Adenosine Receptor Antagonist: a possible approach for the treatment of Parkinson’s Disease. 129
Novel N-6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A(3) adenosine receptors 127
Substituted 6-amino-thiouracils as new P2Y(12) receptor antagonists 126
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 125
Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists 124
Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process 123
Synthesis, biological and modeling studies of new water soluble hA3 adenosine receptor antagonists. 122
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A(3) and A(2B) adenosine receptor subtypes: A molecular modeling investigation 121
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist 121
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4,-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 121
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 121
Rationale design of new human adenosione A3 receptor antagonists through a CoMFA model. 120
Heterocyclic analogs of DNA minor groove alkylating agents 119
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists 119
Current developments of A(2a) adenosine receptor antagonists 119
Synthesis and pharmacological characterization of [3H]-MRE3008F20: the first radioligand antagonist for the human A3 adenosine receptors. 118
null 118
Non peptidic alpha(V)beta(3) antagonists: Recent developments 117
Binding affinity of adenosine receptor agonists and antagonists at human A3 adenosine receptors 117
Synthesis, antiviral and antiproliferative activity of a new class of 5-(alkyl or arylthio)-6-vinyl uracils 117
Synthesis, binding and thermodynamic studies of new highly selective A2A adenosine receptor antagonists 116
Totale 19.409
Categoria #
all - tutte 98.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 548
Totale 99.090


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.361 39 138 78 135 85 51 42 83 38 98 153 421
2022/20231.317 158 63 26 171 220 223 31 118 173 8 73 53
2023/2024810 70 92 34 21 71 60 20 260 12 12 10 148
2024/20252.595 75 134 196 79 329 171 55 201 395 316 379 265
2025/20269.745 660 559 1.299 1.011 901 422 749 334 2.539 893 274 104
2026/2027184 184 0 0 0 0 0 0 0 0 0 0 0
Totale 23.730